Prelude Therapeutics develops precision cancer medicines, including targeted protein degraders and antibody drug conjugates, for patients with underserved cancers. It last closed at $3.32 on Nov 17, down 2.64% on the day.
Only 1 firm rated PRLD in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 261.4% upside
Based on 1 analyst who set a price target on PRLD in the past 90 days. The average target is $12.00, with a high of $12.00 and a low of $12.00, compared with the last close of $3.32.
Low $12.00Avg $12.00High $12.00
Blue marker: last close $3.32
Highest target$12.00
Average target$12.00
Lowest target$12.00
Latest rating changes
JP MorganInitiated
Sep 17Buy$12
HC Wainwright & Co.Reiterated
Jul 29Buy$8
D. Boral CapitalInitiated
May 4Buy$9
Date
Firm
Action
Rating
Price target
Sep 17
JP Morgan
Initiated
Buy
$12
Jul 29
HC Wainwright & Co.
Reiterated
Buy
$8
May 4
D. Boral Capital
Initiated
Buy
$9
Loading…
Technical Analysis
PRLD · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 12% below its 20 day and 18% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot S1 at $3.23, and the nearest resistance the Pivot at $3.36.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.0%/day
Key levels
$6.8352 week high+105.7%
$4.49100 day average+35.2%
$4.11200 day average+23.8%
$3.9250 day average+18.1%
$3.78Swing high (Oct 21)+13.9%
$3.7220 day average+12.0%
$3.45Pivot R1+3.9%
$3.36Pivot+1.2%
$3.32Last close
$3.23Pivot S1−2.7%
$3.18Swing low (Oct 16)−4.2%
$1.3052 week low−60.8%
Indicators
RSI (14)
37.53
Weak, oversold below 30
Neutral
MACD
-0.13
Below its signal line
Bearish
Stochastic
12.6
Near the bottom of its range
Oversold
ADX (14)
17.2
No clear trend
Williams %R
-94.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-130.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−12.2%
Change over 10 sessions
Bearish
ATR (14)
$0.30
Typical daily range, 9.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Turning down
Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityNormal, 23.2%/day
Key levels
$6.8352 week high+105.7%
$4.49100 day average+35.2%
$4.11200 day average+23.8%
$3.9250 day average+18.1%
$3.78Swing high (Oct 21)+13.9%
$3.7220 day average+12.0%
$3.45Pivot R1+3.9%
$3.36Pivot+1.2%
$3.32Last close
$3.23Pivot S1−2.7%
$3.18Swing low (Oct 16)−4.2%
$1.3052 week low−60.8%
Indicators
RSI (14)
43.09
Middle of its range
Neutral
MACD
-0.15
Below its signal line
Bearish
Stochastic
7.6
Near the bottom of its range
Oversold
ADX (14)
32.7
Trending up
Williams %R
-96.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-100.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−27.7%
Change over 10 sessions
Bearish
ATR (14)
$0.77
Typical daily range, 23.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for PRLD
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PRLD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow PRLD usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PRLD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRLD is in one of them and how their past PRLD trades turned out.
Prelude Therapeutics is a precision oncology company based in Wilmington, Delaware. It discovers and develops cancer medicines, including small molecule inhibitors, protein degraders, and antibody drug conjugates, aimed at cancers with limited treatment options. Its pipeline targets driver mutations in blood cancers and solid tumors, such as a JAK2V617F inhibitor for myeloproliferative neoplasms and a KAT6A degrader for advanced breast cancer. The company serves cancer patients and is advancing its candidates through clinical trials.